RE-LY-trial-publication-10-year-anniversary RE-LY-trial-publication-10-year-anniversary Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
Discover your hidden talent with BI Open – the new platform for data science enthusiasts Discover your hidden talent with BI Open – the new platform for data science enthusiasts Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.
Investigational treatment slowed lung function decline in IPF Investigational treatment slowed lung function decline in IPF Investigational treatment slowed lung function decline in IPF
Targeting HER2 in cancer: The story of zongertinib Targeting HER2 in cancer: The story of zongertinib We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
Boehringer Ingelheim Second Transforming Science Day Boehringer Ingelheim Second Transforming Science Day World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day
Living Independence Living Independence Boehringer Ingelheim’s corporate culture is based on values that have been applied since the company was founded in 1885.
Our Expectations Our Expectations We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.
founding-member-of-QUTAC founding-member-of-QUTAC Together, the members of this newly founded consortium want to explore industrial applications for quantum computing
The generalized pustular psoriasis (GPP) Forum 2023 The generalized pustular psoriasis (GPP) Forum 2023 An executive summary of the activities and key takeaways from the GPP Forum 2023
new_analysis_nintedanib_SSc_ILD new_analysis_nintedanib_SSc_ILD Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
Collaboration-with-OxfordBioTherapeutics Collaboration-with-OxfordBioTherapeutics Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
expanded-collaboration-MD-Anderson expanded-collaboration-MD-Anderson The continued collaboration aims to accelerate the development of KRAS and TRAILR2 compounds in lung cancer
Phase II results cognitive impairment schizophrenia Phase II results cognitive impairment schizophrenia Presented at ECNP Congress, Phase II trial results demonstrated improvement in cognition with BI 425809 in schizophrenia patients
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Bees and biodiversity Bees and biodiversity At Boehringer Ingelheim we attach great importance to sustainable planting on our company site – and to protecting the bees.
Boehringer Ingelheim announces appointments Boehringer Ingelheim announces appointments Boehringer Ingelheim announces appointments
License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments
Making a difference with data science Making a difference with data science Our Head of Central Data Science, Brigitte Fuhr joined the team to make a difference to patients’ lives.
Lothar Halmer Lothar Halmer Dr. Lothar Halmer is Chief Quality Officer and leads the Global Quality Organization in providing quality products for our patients every day.
GPP Forum Article - Frida Dunger Johnsson, Executive Director, IFPA GPP Forum Article - Frida Dunger Johnsson, Executive Director, IFPA Frida Dunger Johnsson, Executive Director of IFPA and panelist at the generalized pustular psoriasis (GPP) Forum, reflects on a momentous day
Why cancer care is personal for us Why cancer care is personal for us At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Disentangling fibrosis Disentangling fibrosis Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Ileitis prevention vaccination Lawsonia intracellularis pig Ileitis prevention vaccination Lawsonia intracellularis pig Cause, impact and prevention: Learn the essentials about Ileitis
Boehringer acquires T3 Pharma Boehringer acquires T3 Pharma Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Interview with Michael Schmelmer Interview with Michael Schmelmer "You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors